Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia

被引:46
作者
Vessey, Donald A. [1 ,3 ]
Li, Luyi [1 ]
Kelley, Michael [1 ]
Karliner, Joel S. [2 ,3 ,4 ]
机构
[1] Dept Vet Affairs Med Ctr, Liver Study Unit 151 K, San Francisco, CA 94121 USA
[2] Dept Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA
关键词
cardioprotection; ischemia; postconditioning; sphingosine; sphingosine-1-phosphate;
D O I
10.1016/j.bbrc.2008.08.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Both sphingosine and sphingosine-1-phosphate (S1P) were able to protect the ex vivo rat heart from ischemia reperfusion injury when added to the perfusion medium at the time of reperfusion after a 40 min ischemia (postconditioning). Inhibitor studies revealed distinct mechanisms of protection, with S1P employing a G-protein Coupled receptor pathway and sphingosine a cyclic nucleotide dependent protein kinase pathway. However, both restored ischemia-induced depletion of phospho-AKT. Extending the ischemia to 75 min reduced protection by both S1P and sphingosine, but protection could be enhanced by employing them in combination. Extending the time of ischemia further to 90 min almost eliminated cardioprotection by S1P OF sphingosine; and their combination gave only modest protection. However, when S1P plus sphingosine was combined with a novel ramped ischemic postconditioning regimen, left ventricle developed pressure recovered by 66% and there was only a 6% infarct size. The data indicate that detrimental changes are accumulating during protracted ischemia but for up to 90 min this damage is not irreversible and hearts can still recover with proper treatment. Published by Elsevier Inc.
引用
收藏
页码:425 / 429
页数:5
相关论文
共 17 条
[1]   Modes of myocardial cell injury and cell death in ischemic heart disease [J].
Buja, LM ;
Entman, ML .
CIRCULATION, 1998, 98 (14) :1355-1357
[2]   Sphingosine 1-phosphate analogs as receptor antagonists [J].
Davis, MD ;
Clemens, JJ ;
Macdonald, TL ;
Lynch, KR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (11) :9833-9841
[3]   ADAPTATION TO ISCHEMIA DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY - CLINICAL, HEMODYNAMIC, AND METABOLIC FEATURES [J].
DEUTSCH, E ;
BERGER, M ;
KUSSMAUL, WG ;
HIRSHFELD, JW ;
HERRMANN, HC ;
LASKEY, WK .
CIRCULATION, 1990, 82 (06) :2044-2051
[4]   Losing heart: the role of apoptosis in heart disease - a novel therapeutic target? [J].
Gill, C ;
Mestril, R ;
Samali, A .
FASEB JOURNAL, 2002, 16 (02) :135-146
[5]   MYOCARDIAL REPERFUSION INJURY - EXPERIMENTAL-EVIDENCE AND CLINICAL RELEVANCE [J].
HANSEN, PR .
EUROPEAN HEART JOURNAL, 1995, 16 (06) :734-740
[6]   THE CELL BIOLOGY OF ACUTE MYOCARDIAL-ISCHEMIA [J].
JENNINGS, RB ;
REIMER, KA .
ANNUAL REVIEW OF MEDICINE, 1991, 42 :225-246
[7]   A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury [J].
Jin, Zhu-Qiu ;
Zhang, Jianqing ;
Huang, Yong ;
Hoover, Holly E. ;
Vessey, Donald A. ;
Karliner, Joel S. .
CARDIOVASCULAR RESEARCH, 2007, 76 (01) :41-50
[8]   Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKCε knockout mouse hearts [J].
Jin, ZQ ;
Zhou, HZ ;
Zhu, PL ;
Honbo, N ;
Mochly-Rosen, D ;
Messing, RO ;
Goetzl, EJ ;
Karliner, JS ;
Gray, MO .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 282 (06) :H1970-H1977
[9]   Identification of a novel role for sphingolipid signaling in TNFα and ischemic preconditioning mediated cardioprotection [J].
Lecour, S ;
Smith, RM ;
Woodward, B ;
Opie, LH ;
Rochette, L ;
Sack, MN .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2002, 34 (05) :509-518
[10]   Reperfusion injury: A review of the pathophysiology, clinical manifestations and therapeutic options [J].
Maxwell, SRJ ;
Lip, GYH .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1997, 58 (02) :95-117